Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. Feagan BG, et al. Among authors: fedorak rn. N Engl J Med. 2000 Jun 1;342(22):1627-32. doi: 10.1056/NEJM200006013422202. N Engl J Med. 2000. PMID: 10833208 Free article. Clinical Trial.
Review and clinical perspectives for the use of infliximab in ulcerative colitis.
Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Panaccione R, et al. Among authors: fedorak rn. Can J Gastroenterol. 2008 Mar;22(3):261-72. doi: 10.1155/2008/493405. Can J Gastroenterol. 2008. PMID: 18354755 Free PMC article. Review.
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. Khanna R, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2013 Sep;38(5):447-59. doi: 10.1111/apt.12407. Epub 2013 Jul 14. Aliment Pharmacol Ther. 2013. PMID: 23848220 Review.
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Feagan BG, et al. Among authors: fedorak rn. Aliment Pharmacol Ther. 2015 Nov;42(10):1170-81. doi: 10.1111/apt.13398. Epub 2015 Sep 23. Aliment Pharmacol Ther. 2015. PMID: 26400458 Clinical Trial.
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Schreiber S, et al. Among authors: fedorak rn. Gastroenterology. 2000 Dec;119(6):1461-72. doi: 10.1053/gast.2000.20196. Gastroenterology. 2000. PMID: 11113067 Clinical Trial.
283 results